[64Cu]PD-32766 and [177Lu]PD-32766, a new theranostic pair for CAIX-expressing tumors
May 6, 2024
Researchers from Peptidream Inc. presented preclinical characterization of novel carbonic anhydrase IX (CAIX)-targeting radiopeptides, [64Cu]PD-32766 and [177Lu]PD-32766, being developed for the diagnosis and treatment of clear cell renal cell carcinoma (ccRCC), respectively.